Dr Reddys Laboratories announces launch of Levalbuterol Inhalation Solution

In US market on 23 September 2014

Dr Reddys Laboratories announced that the Company has launched Levalbuterol Inhalation Solution (for oral inhalation only), USP 0.31 mg/3 mL, 0.66 mg/ 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of XOPENEX inhalation solution in the US market on 23 September 2014, approved by the United States Food & Drug Administration (USFDA).

Powered by Capital Market - Live News